Comparison of the Skin Conductance Values and Patient Pain Scores During Minor Procedures in the ICU

Pain Clinical Trial

— ICUPAIN  

Official title:

Comparison of the Skin Conductance Values and Patient Pain Scores During Minor Procedures in the ICU

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02934308
• Other study ID #: 2014-66
• Secondary ID: 2014-A01770-47
• Status: Completed
• Phase: N/A
• First received: October 13, 2016
• Last updated: January 24, 2018
• Start date: September 15, 2015
• Est. completion date: October 10, 2017

Study information

• Verified date: January 2018
• Source: Hopital Foch
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Pain in hospitalized patients has received increasing attention, however due to its subjective nature, it has defied objective, quantitative measurements. If a patient is able to communicate, pain may be assessed using standardized sentences, visual analog scales (VAS) or plain numeric scales.When a patient is unable to communicate, a method that would allow the caregiver to continuously monitor patients' pain and alert the provider that the patient may be in pain would be quite useful. The Pain Monitor uses a novel measurement technique of analyzing changes in skin conductance that can be used in patients who are unable to provide a subjective pain score. This study will compare the relationship between the measurements taken by the PainMonitor and pain scores given by communicative patients to evaluate the safety and efficacy of this monitor during planned, routine procedures.

Description:

Although pain must be assessed to be treated, it has been challenging to obtain consistent, objective, and quantifiable measurements. The best methods currently available are subjective scales communicated by the patient such as standardized sentences, visual analog scales (VAS), or plain numeric scales. When a patient is unable to communicate, methods used to monitor pain are inadequate. A device that provides an objective assessment of pain in these patients would alert the patient's caregivers that the patient may be in pain and analgesic treatment is indicated.

Various methods (Evans et al, 2013; Kantor, 2014; Isnardon, 2013) have been proposed to monitor patients' reactions to nociceptive stimulation such as:

• changes in heart rate or blood pressure

• changes in microcirculation

• pupillometry

• EEG

• Auditory or somatosensory evoked potentials All of these methods have been found lacking, mostly due to a lack of specificity for pain. Pupillometry is not suitable for long periods of measurement and is sensitive to concomitant treatment (e.g. opioids).

Galvanometry has the potential to provide specific information related to pain in patients who are unable to communicate.

Since sweat glands are the only organs controlled solely by the sympathetic nervous system, there is a reasonable chance that the use of galvanometry can provide a reliable means of assessing pain. There are numerous papers on this topic; searching in PUBmed on the key words "pain" and "skin conductance" results in more than 250 papers (selected references are included in the list below). The PainMonitor system uses galvanometry to monitor changes in skin conductance responses per sec mirroring the number of bursts in the skin sympathetic nerves. This creates a warning for caregivers to assess the potential that the patient is in pain.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 67
• Est. completion date: October 10, 2017
• Est. primary completion date: October 10, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 89 Years

Eligibility

Inclusion Criteria:

• Patients between the ages of 18-89 years (inclusive), in an adult ICU

• Patients admitted to the ICU who are able to communicate their pain and anxiety using a VAS

• Patients must be cooperative and not agitated.

• Planned to have a potentially painful procedure

Exclusion Criteria:

• Diagnosed neuropathic disease

• Use of neostigmine within the past 3 hours

• Use of regional anesthesia at the extremity where the device electrodes are placed -

Related Conditions & MeSH terms

• Pain

Intervention

Device:
• Skin Conductance Monitor

Locations

Country	Name	City	State
France	Hôpital Foch	Suresnes

Sponsors (1)

Lead Sponsor	Collaborator
Hopital Foch

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sensitivity and specificity with a confidence interval	Sensitivity and specificity with a confidence interval > 80 % when skin conductance responses per sec are > 0.13 and VAS is equal to or greater than 30 mm. This end point will be reached by 100 patients with at least 10 discrete measurements for each patient.	1 year